Sandoz Sued Over Schizophrenia Drug Patent

Law360, New York (March 5, 2007, 12:00 AM EST) -- A Japanese pharmaceutical company has filed a patent infringement suit against the generics arm of Novartis AG in response to the subsidiary’s bid to obtain U.S. regulatory approval for a generic version of schizophrenia and bipolar disorder treatment Abilify.

Tokyo-based Otsuka Pharmaceutical Co. Ltd. filed the lawsuit Friday in New Jersey against Sandoz Inc., seeking to bar Sandoz’ proposed generics from entering the U.S. market until the expiration of an Otsuka patent.

At issue is U.S. Patent Number 5,006,528, entitled “carbostyril derivatives,” which was issued and...
To view the full article, register now.